Abstract

Arterial and venous thromboembolism are both more common in older adults. The use of anticoagulants, the mainstay to prevent thromboembolism, requires consideration of the balance between risk and benefit. Such consideration is even more important in the very elderly in whom the risk of anticoagulant-related bleeding and thrombosis are higher. This review will focus on the challenges of implementing and managing anticoagulant therapy in older patients in an era when the options for anticoagulants include not only vitamin K antagonists (VKAs), but also direct-acting oral anticoagulants (DOACs).

Highlights

  • Arterial and venous thromboembolism are both more common in older adults

  • The risk reduction (RR) in stroke and systemic embolism was similar (P-interaction = 0.38) in patients ≥75 years old (RR 0.78; 95% confidence interval (CI): 0.66–0.88) and in those

  • Both arterial and venous thromboembolism are more common in older adults, but so is the risk of anticoagulant-related bleeding

Read more

Summary

Thromboembolism in Older Adults

Arterial and venous thromboembolism are both more common in older adults. The use of anticoagulants, the mainstay to prevent thromboembolism, requires consideration of the balance between risk and benefit. Such consideration is even more important in the very elderly in whom the risk of anticoagulant-related bleeding and thrombosis are higher. This review will focus on the challenges of implementing and managing anticoagulant therapy in older patients in an era when the options for anticoagulants include vitamin K antagonists (VKAs), and direct-acting oral anticoagulants (DOACs). Reviewed by: Danuza Esquenazi, Oswaldo Cruz Foundation (Fiocruz), Brazil Paolo Prandoni, Arianna Foundation on Anticoagulation, Italy. Specialty section: This article was submitted to Geriatric Medicine, a section of the journal

GENERAL CONSIDERATIONS IN THE ANTITHROMBOTIC MANAGEMENT OF OLDER ADULTS
Chronic Kidney Disease
The Elderly in the DOAC Trials of SPAF
Practical Considerations in Dosing DOACs for SPAF in the Elderly
The Case to Continue VKA in a Stable Patient
VENOUS THROMBOEMBOLISM IN THE ELDERLY
Practical Considerations in Dosing DOACs for VTE Treatment in the Elderly
Findings
CONCLUSION
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.